摘要
尽管对列腺癌(PCA)的早期诊断取得了相当大的进展,但在西方国家,前列腺癌(PCA)任是因癌症导致死亡的第二大原因。事实上,由于其对抗癌药物的反应性差,在疾病的早期阶段,虽然存在有效的治疗方法,但对晚期前列腺癌的治疗却十分有限。这些都表明迫切需要寻求新的和更有效的治疗方法。microRNAs是一种短的非编码RNA,它能通过转录后水平调控PCA细胞的基因表达,microRNAs的失调和其同时调节多种致癌/抑癌途径的潜力,引起了人们对特定miRNA表达的改变以及PCA对抗癌药物的反应的功能之间关系的兴趣。本文对PCA相关miRNA作为潜在的新型治疗靶点/工具,和其在调节PCA对抗癌药物的反应发挥的作用进行了归纳总结。
关键词: 抗肿瘤药物,microRNA,前列腺癌。
Current Drug Targets
Title:MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Volume: 17 Issue: 3
Author(s): Marzia Pennati, Marco Folini, Paolo Gandellini and Nadia Zaffaroni
Affiliation:
关键词: 抗肿瘤药物,microRNA,前列腺癌。
摘要: Despite considerable advances in early diagnosis, prostate cancer (PCa) remains the second leading cause of cancer-related deaths in men in western countries. In fact, although efficient therapies exist for early-stage disease, the treatment of advanced PCa remains unsuccessful mainly due to its poor responsiveness to anti-cancer agents. This evidence underlines the urgent need for the development of novel and more effective therapeutic approaches. In this context, the documented dysregulation of microRNAs (miRNAs) -which are short non-coding RNAs that regulate gene expression at post-transcriptional level- in PCa, together with their potential to simultaneously regulate multiple oncogenic/ tumor-suppressive pathways, has stimulated interest in defining a functional association between altered expression of specific miRNAs and the response of PCa to anti-cancer agents. The purpose of this review is to provide an overview on PCa-related miRNAs as potential novel therapeutic targets/tools, with a special focus on the role that they may play in conditioning the responsiveness of PCa to anti-cancer drugs.
Export Options
About this article
Cite this article as:
Marzia Pennati, Marco Folini, Paolo Gandellini and Nadia Zaffaroni , MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666150316223341
DOI https://dx.doi.org/10.2174/1389450116666150316223341 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Preparation and Characterization of PEGylated C18 Fatty Acids/Anti-SNAP25 Antibody-Targeted Liposomes
Current Chemical Biology Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Optimization and Evaluation of Micromeritic and Release Properties of High Dose Flutamide Liquisolid Systems
Letters in Drug Design & Discovery Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Recent Patents on New Steroid Agents Targeting the Steroidogenesis for Endocrine Cancer Treatments
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or İllusion?
Current Pharmaceutical Design Lipid-based Self-Adjuvanting Vaccines
Current Drug Delivery Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Expression Profile of Genes Associated with the Proteins Degradation Pathways in Colorectal adenocarcinoma
Current Pharmaceutical Biotechnology The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Synthesis and Biochemical Evaluation of a Range of 4-(n-alkanesulfonate) benzyl Imidazole-Based Compounds as Inhibitors of Rat Testicular 17α-hydroxylase/17,20-lyase (P450<sub>17α</sub>) in the Treatment of Hormone- Dependent Prostate Cancer
Letters in Drug Design & Discovery